Butanserin (INNTooltip International Nonproprietary Name; developmental code name R-53393) is a serotonin 5-HT2 receptor antagonist and α1-adrenergic receptor antagonist which was studied as an antihypertensive agent but was never marketed.[1][2][3] It was first described in the scientific literature by 1984.[1][2][3]

See also

References

  1. 1 2 Elks, J. (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 16 January 2026.
  2. 1 2 Megens AA, Niemegeers CJ (August 1984). "Antagonism of the antidiarrhoeal effect of clonidine and the lethal effect of noradrenaline in rats: a reliable procedure to evaluate the in-vivo alpha 1- and alpha 2-blocking activity of drugs?". J Pharm Pharmacol. 36 (8): 516–520. doi:10.1111/j.2042-7158.1984.tb04442.x. PMID 6148393.
  3. 1 2 Korstanje C, Sprenkels R, Doods HN, Hugtenburg JG, Boddeke E, Batink HD, Thoolen MJ, Van Zwieten PA (May 1986). "Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2- and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT2-receptors: comparison with ketanserin". J Pharm Pharmacol. 38 (5): 374–379. doi:10.1111/j.2042-7158.1986.tb04590.x. PMID 2872314.
source: https://en.wikipedia.org/wiki/Butanserin